文章：

慢性淋巴细胞白血病治疗流程图2022

Chronic lymphocytic leukemia treatment algorithm 2022

原文发布日期：2022-11-29

DOI: 10.1038/s41408-022-00756-9

类型: Current Treatment Algorithm

开放获取: 是

英文摘要：

The treatment landscape for patients with chronic lymphocytic leukemia (CLL) has changed considerably with the introduction of very effective oral targeted therapies (such as Bruton tyrosine kinase inhibitors and venetoclax) and next-generation anti-CD20 monoclonal antibodies (such as obinutuzumab). These agents lead to improved outcomes in patients with CLL, even among those with high-risk features, such as del17p13 or TP53 mutation and unmutated immunoglobulin heavy chain (IGHV) genes. Selecting the right treatment for the right patient requires consideration of disease characteristics and prior treatment sequence, as well as patient preferences and comorbidities. The CLL-International Prognostic Index (CLL-IPI) remains the best-validated tool in predicting the time to first therapy among previously untreated patients, which guides selection for early intervention efforts. This review summarizes our current approach to the management of CLL, right from the time of diagnosis through relapsed disease.
 

摘要翻译： 

慢性淋巴细胞白血病（CLL）的治疗格局因高效口服靶向药物（如布鲁顿酪氨酸激酶抑制剂与维奈克拉）及新一代抗CD20单克隆抗体（如奥滨尤妥珠单抗）的问世而发生显著变化。这些药物能改善CLL患者的预后，即使存在高危因素（如del17p13或TP53突变、未突变的免疫球蛋白重链基因）的患者亦能获益。为患者选择合适的治疗方案需综合考虑疾病特征、既往治疗历程、患者意愿及合并症。CLL国际预后指数（CLL-IPI）仍是预测初治患者首次治疗时间最有效的工具，可指导早期干预策略的选择。本综述系统阐述当前CLL的全程管理策略，涵盖从初诊到疾病复发的各个阶段。

原文链接：

Chronic lymphocytic leukemia treatment algorithm 2022